Cardiovascular Disease | Norton Healthcare

Indication: Cardiovascular Disease

ZEUS – Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

Sub-indication: Cardiovascular Disease

Study Type: Drug Study

Principal Investigator: Jason A. Hopper, M.D.
Norton Heart & Vascular Institute

Sponsor: Sponsor: Novo Nordisk, Inc.

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.